AIP
UTHR icon

Arrowpoint Investment Partners’s United Therapeutics UTHR Stock Holding History

Arrowpoint Investment Partners’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-2,500
Closed -$1.07M – 145
2025
Q3 		$1.07M Buy
+2,500
New +$841K 1.07% 26

Other funds holding UTHR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Norges Bank
Norges Bank Oslo, Norway $1T AUM

Arrowpoint Investment Partners's UTHR Position: Q2 2026 in Review

Arrowpoint Investment Partners increased its United Therapeutics (UTHR) stake by 96% in Q2 2026, buying an estimated $286K and bringing the position to 1,035 shares worth $561K. The position accounts for 0.12% of the portfolio, ranked #72.

Arrowpoint Investment Partners first reported a position in UTHR in Q1 2026 and has held it in 2 quarters since. 882 funds tracked by Wall St. Rank hold UTHR as of Q2 2026.

  • Arrowpoint Investment Partners held 1,035 shares of United Therapeutics worth $561K as of Q2 2026.
  • Arrowpoint Investment Partners bought 508 United Therapeutics shares in Q2 2026, an estimated $286K.
  • United Therapeutics made up 0.12% of Arrowpoint Investment Partners's portfolio in Q2 2026, its #72 holding.
  • Arrowpoint Investment Partners first reported a position in United Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 882 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2026.

Based on Arrowpoint Investment Partners's 13F filing for Q2 2026, filed 13 Aug 2026.